CRISPR Therapeutics (NASDAQ:CRSP) Releases Earnings Results, Beats Estimates By $0.71 EPS

CRISPR Therapeutics (NASDAQ:CRSP) posted its earnings results on Tuesday. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71, Zacks reports. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP traded up $0.21 during trading on Tuesday, reaching $39.62. 2,007,161 shares of the company traded hands, compared to its average volume of 1,931,213. CRISPR Therapeutics has a 1-year low of $36.52 and a 1-year high of $91.10. The stock’s 50 day moving average price is $42.77 and its two-hundred day moving average price is $46.53. The company has a market cap of $3.38 billion, a price-to-earnings ratio of -14.00 and a beta of 1.67.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 15,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the sale, the chief executive officer now directly owns 181,540 shares of the company’s stock, valued at $10,002,854. This trade represents a 7.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on CRSP shares. Chardan Capital reissued a “buy” rating and issued a $94.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $53.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. JMP Securities restated a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a report on Friday, December 20th. Finally, HC Wainwright began coverage on CRISPR Therapeutics in a research note on Monday, February 3rd. They issued a “buy” rating and a $65.00 price objective on the stock. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $77.59.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.